NPM1 and acute myeloid leukemia: Followinga primary screening in CSC models, we identified the novel compoundUCM-13369 (4b) whose cytotoxicity was mediated by NPM1.This protein is one of the most frequent mutations of AML, and NPM1-mutatedAML is recognized by the WHO as a distinct hematopoietic malignancy.UCM-13369 inhibits NPM1 expression, downregulates the pathway associatedwith mutant NPM1 C+, and specifically recognizes the C-end DNA-bindingdomain of NPM1 C+, avoiding the nucleus-cytoplasm translocation involvedin the AML tumorological process.